KURA

Sinker

Kura Oncology, Inc. · Healthcare · United States · $855M cap · $16.6M/day traded

$7.34 -2.0% · close 18 Nov · scored 19 Nov

Score down 1.1 since 18 Nov: Momentum down 3 after a 2% price fall.

Sinker: Weak business, rich price and weak momentum. Nothing here to keep it afloat.

5
Score
Get score and insider alerts
Quality
14
Value
22
Momentum
36

As of 19 Nov 2026, the MoatMap Score for Kura Oncology, Inc. (KURA) is 5/100, ranked against 25,000+ stocks in 38 markets (Quality 14, Value 22, Momentum 36, each scored against its sector).

Does the score work? Each tenth of the ranking, tracked monthly. See the record →

P/E (TTM)
—
peers 27.0x
ROE
-224.9%
peers -29.9%
D/E
1.4x
peers 0.2x
Dividend %
—
trailing yield

ABOUT KURA ONCOLOGY, INC.

Read

Kura Oncology is a clinical-stage biotechnology company dedicated to discovering and developing precision medicines for cancer, particularly targeting farnesyl transferase and other cancer pathways. Its competitive edge lies in proprietary drug candidates with novel mechanisms of action and a pipeline addressing significant unmet needs in oncology. The company's lead candidate, ziftomenib, is in late-stage clinical trials for acute myeloid leukemia (AML).

FINANCIAL SUMMARY (USD)

Year20212022202320242025CAGRTTM2026E2027EFwd CAGR
Income and shares
Revenue———53.9M67.5M25.2%79.3M94.0M—39.3%
Net margin—n/mn/m-322.9%-412.9%—————
EPS-2.0-2.0-2.1-2.0-3.2—-3.3-3.2-2.4—
Share count66.6M68.3M74.3M78.2M87.9M7.2%91.9M———
Balance sheet
Debt—14.0M17.2M16.6M20.5M13.4%25.8M———
Equity506.6M420.3M397.3M413.6M174.1M-23.4%————
Debt/equity—0.0x0.0x0.0x0.1x+0.1x————
Cash flow
Op. cash flow-104.6M-110.1M-124.8M134.3M-64.1M—-85.6M———
Cash flow margin—n/mn/m249.3%-94.9%—-107.9%———
Investing CF-126.8M32.6M15.6M-101.6M-13.1M—————
Financing CF-3.4M38.6M94.8M154.4M1.8M—————

Cash on hand equals about 5.8 years of the operating cash used in the last twelve months. Spending on equipment or exploration and any new funding are not counted.

PRICE (1Y) · USD-30.2%
6.87.88.89.710.78 Oct29 Oct18 Nov
SMA 50SMA 200

Price checkStill fallingExperimental

Made a new 52-week low 8 trading days ago, 47% below its 52-week high. The fall has not stopped yet.

SwingsVery bumpy

Swung more than 77% of stocks we rank over the past year (volatility 63% a year).

How this is worked out

The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.

  • Still falling (this stock): It set a new 52-week low in the last two weeks, after a deep fall.
  • Finding a floor: It fell hard, but has set no new low for more than two weeks.
  • Turning up: It has climbed off its low and is back above a rising 50-day average.
  • In an uptrend: It is near its 52-week high and above its 200-day average.
  • No clear trend: None of the above: no recent deep fall and no steady climb.
  • No read yet: Not enough price history yet: it needs a year of trading.

In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.

The exact rules

Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.

What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.

Calm is not safe: a calm stock can still slide steadily.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
$7.34
RSI (14)
26.1
52-Week Range-47.2% from high
Low $6.75High $13.90

SCORE BREAKDOWN

Quality
14
ROIC
-46.9%17.0
ROE
-224.9%3.7
GP/Assets
-24.4%3.8
Op. Margin
-394.3%10.1
FCF/Assets
-12.1%28.5
Piotroski
25.8
Int. Cover
-50.0x5.8
D/E Ratio
1.44x8.1
Current Ratio
3.60x62.9
Value
22
P/E (TTM)
—N/A
EV/EBITDA
-0.8x25.0
P/FCF
—N/A
P/B
39.8x1.7
P/S
9.0x24.9
Div Yield
—N/A
Momentum
36
52W High %
53%34.4
RS 6M
-28%20.5
SMA 50/200
1.01x64.9
EPS Rev 4W
-1.7%16.7
EPS Rev 12W
+7.4%80.0
EPS Improve
+28%41.5
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$855M
P/E (Forward)
-3.3x
Gross Margin
99.9%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KURA are excluded.

TickerCompanyMkt CapScore
KURAKura Oncology, Inc.(you)$855M5
OBXObsidian Therapeutics, Inc.$864M6
ALMSAlumis Inc.$878M3
950260.KQIngenia Therapeutics Inc.$808M6
CRVSCorvus Pharmaceuticals, Inc.$886M7
AKTSAktis Oncology, Inc.$875M8
SVRASavara Inc.$867M9
IAMIambic Therapeutics, Inc.$676M5
ANNXAnnexon, Inc.$711M3
ACHVAchieve Life Sciences, Inc.$669M5

Peer medians: ROE -29.9% · P/E 27.0x · Gross margin 63.3%

Company Deep Dive

A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.

Request Deep Dive(50 Feathers)

Kura Oncology, Inc. (KURA): Stock Score Summary

Kura Oncology, Inc. (KURA) has a MoatMap Score of 5/100 based on Quality (14/100), Value (22/100), and Momentum (36/100) factor scores.

Kura Oncology is a clinical-stage biotechnology company dedicated to discovering and developing precision medicines for cancer, particularly targeting farnesyl transferase and other cancer pathways. Its competitive edge lies in proprietary drug candidates with novel mechanisms of action and a pipeline addressing significant unmet needs in oncology. The company's lead candidate, ziftomenib, is in late-stage clinical trials for acute myeloid leukemia (AML).

Director dealings

From 2 Jan 2026 to 19 Nov 2026, MoatMap's records hold 22 sales and 4 purchases of Kura Oncology, Inc. (KURA) shares by its directors. The largest: WILSON TROY EDWARD bought 100,000 shares at $12.39 on 24 Aug 2026 (about $1.2M).

  • 16 Nov 2026: WILSON TROY EDWARD bought 101,119 shares at $7.42 (about $750K)
  • 13 Nov 2026: WILSON TROY EDWARD bought 98,881 shares at $7.63 (about $754K)
  • 29 Sep 2026: FORD KATHLEEN sold 3,668 shares at $10.75 (about $39K)
  • 29 Sep 2026: Leoni Mollie sold 28,802 shares at $10.75 (about $310K)
  • 29 Sep 2026: Powl Brian T. sold 15,430 shares at $10.75 (about $166K)
KURA insider filings, last 180 days

Key Financial Metrics

Price$7.34
Market Cap$855M
P/E (Forward)-3.25
Price/Book39.85
Return on Equity-224.9%
Return on Invested Capital-46.9%
Debt/Equity1.44x
Gross Margin99.9%
Operating Margin-394.3%
Revenue Growth10.1%
Free Cash Flow$-89M

Kura Oncology, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Kura Oncology, Inc.’s (KURA) MoatMap Score?
The MoatMap Score for Kura Oncology, Inc. (KURA) is 5/100. It is a composite of Quality (14), Value (22), and Momentum (36), each scored against its sector. The composite is then ranked across MoatMap’s universe of 25,000+ stocks.
Does Kura Oncology, Inc. have an economic moat?
Kura Oncology, Inc. (KURA) has a Quality factor score of 14/100. Quality blends several measures of profitability and financial strength, led by gross profit to assets, return on invested capital and free cash flow to assets. A high score describes the financial record a durable advantage tends to leave; it does not prove a moat.
What sector is Kura Oncology, Inc. in?
Kura Oncology, Inc. (KURA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).